STAT+: Editas Medicine names new CEO — its fourth — as delays, poor data hamper its gene-editing treatments
Editas Medicine announced the hiring of a new CEO on Thursday — the fourth top executive to lead the troubled maker of gene-editing treatments since 2014.
Gilmore O’Neill takes over as Editas’ CEO on June 1, the company said. He joins the company from Sarepta Therapeutics, where he served as chief medical officer.
